Lung Cancer Gene Fusion Assays using NanoString® nCounter® Technology

Testing in NTRK Fusion-Positive Lung CancerПодробнее

nCounter Technology by NanoString - Direct Detection for Gene and Protein Expression ProfilingПодробнее

NanoString Technologies: Q&A with Dr. Sean Ferree on RNA Signature DevelopmentПодробнее

Limitations in genetic testing for lung cancerПодробнее

Adding CNVs and Fusions to a Lung cfDNA Assay: Impact on Oncology Clinical ResearchПодробнее

NanoString Technologies: Q&A with Dr. Joe Beechem on Pathway BiologyПодробнее

What are NTRK Gene Fusions?Подробнее

Brief nCounter: Learn how nCounter Panels cover the new Hallmarks of Cancer!Подробнее

Dr. Ranee Mehra on Molecular Testing in NSCLCПодробнее

Genomic testing for lung cancer in the UKПодробнее

Lung cancer genotyping with NGSПодробнее

Christian Lytle - New multiplexed nCounter® PlexSet™ Reagents- an alternative to qPCR technologyПодробнее

Entrectinib in NTRK fusion-positive non-small cell lung cancerПодробнее

NanoString Scientists Reveal the “Secret Sauce” in Lysate Protocol DevelopmentПодробнее

The detection of NTRK gene fusions in NSCLCПодробнее

Nanostring Technology: Identifying SubtypesПодробнее

Genomic Landscape of Lung Cancer: Key Mutations & Targeted TherapiesПодробнее

Spatial Biology Revealed with the GeoMx DSP by NanoStringПодробнее

Genomic Testing Is Necessary in Non-Small Cell Lung CancerПодробнее